Review of: "[Review Article] Nanocarriers for Protein and Peptide Drug Delivery"

Borislav Angelov[1]

1 Extreme Light Infrastructure Beamlines

Potential competing interests: No potential competing interests to declare.

I have the following suggestions for improvement of the paper:

1. The sentence in the abstract background: "Protein and peptide drugs offer significant promise as therapeutic agents due to their superior efficacy and reduced toxicity compared to conventional chemical drugs" should be checked carefully since the toxicity is a very specific property dependent on the concentration. The toxicity of a substance is often assessed by evaluating its effects at different concentrations to determine a therapeutic window, which represents the range between the effective dose and the dose at which toxic effects occur.

2. The section "iv) Nanoparticles" contains the following subsections: a) Liposomes, b) Protein-based nanoparticles, c) Polymeric Nanoparticles, d) Inorganic Nanoparticles, e) Solid Lipid based Nanoparticles. It is important to note that this classification is not universally accepted. However, when discussing liposomes, it is logical to continue with other lipid-based drug delivery systems such as micelles, emulsions, and liquid crystalline cubosomes before addressing solid lipid nanoparticles.

3. Figure 2 contains the plant protein sources along with the nanocarrier systems. It is better to separate the nanocarrier system separately. Figure 1, for example, does not contain the corresponding nanocarrier systems.